Trial Profile
Impact of Sustained virological response (SVR) on the liver fibrosis regression in HCV infected patients after the Direct-acting antiviral therapy (DAA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases